inzy-10q_20210630.htm
false Q2 0001693011 --12-31 true true true true true P8Y9M3D P8Y7M13D P7Y9M7D P8Y7M13D P5Y4M13D P6Y9M10D P5Y4M13D P6Y9M10D 0.0092 0.0048 0.0115 0.0115 P6Y29D P6Y5M23D 0.9034 0.8870 0.9119 0.9119 0001693011 2021-01-01 2021-06-30 xbrli:shares 0001693011 2021-08-06 iso4217:USD 0001693011 2021-06-30 0001693011 2020-12-31 iso4217:USD xbrli:shares 0001693011 2021-04-01 2021-06-30 0001693011 2020-04-01 2020-06-30 0001693011 2020-01-01 2020-06-30 0001693011 us-gaap:CommonStockMember 2020-12-31 0001693011 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001693011 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001693011 us-gaap:RetainedEarningsMember 2020-12-31 0001693011 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001693011 2021-01-01 2021-03-31 0001693011 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001693011 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001693011 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001693011 us-gaap:CommonStockMember 2021-03-31 0001693011 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001693011 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001693011 us-gaap:RetainedEarningsMember 2021-03-31 0001693011 2021-03-31 0001693011 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001693011 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001693011 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001693011 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001693011 us-gaap:CommonStockMember 2021-06-30 0001693011 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001693011 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001693011 us-gaap:RetainedEarningsMember 2021-06-30 0001693011 inzy:SeriesAConvertiblePreferredStockMember 2019-12-31 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember 2019-12-31 0001693011 us-gaap:CommonStockMember 2019-12-31 0001693011 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001693011 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001693011 us-gaap:RetainedEarningsMember 2019-12-31 0001693011 2019-12-31 0001693011 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001693011 2020-01-01 2020-03-31 0001693011 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001693011 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001693011 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001693011 inzy:SeriesAConvertiblePreferredStockMember 2020-03-31 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember 2020-03-31 0001693011 us-gaap:CommonStockMember 2020-03-31 0001693011 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001693011 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001693011 us-gaap:RetainedEarningsMember 2020-03-31 0001693011 2020-03-31 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember 2020-04-01 2020-06-30 0001693011 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001693011 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001693011 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001693011 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001693011 inzy:SeriesAConvertiblePreferredStockMember 2020-06-30 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember 2020-06-30 0001693011 us-gaap:CommonStockMember 2020-06-30 0001693011 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001693011 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001693011 us-gaap:RetainedEarningsMember 2020-06-30 0001693011 2020-06-30 0001693011 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-01-01 2021-06-30 0001693011 2020-01-01 2020-12-31 0001693011 us-gaap:AccountingStandardsUpdate201602Member 2021-06-30 0001693011 us-gaap:AccountingStandardsUpdate201602Member 2021-01-01 0001693011 us-gaap:AccountingStandardsUpdate201602Member srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2021-01-01 0001693011 us-gaap:AccountingStandardsUpdate201815Member 2021-06-30 0001693011 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-01-01 2021-06-30 0001693011 us-gaap:USTreasurySecuritiesMember 2021-01-01 2021-06-30 0001693011 inzy:USGovernmentAgencyDebtSecuritiesMember 2021-01-01 2021-06-30 0001693011 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-06-30 0001693011 us-gaap:USTreasurySecuritiesMember 2021-06-30 0001693011 inzy:USGovernmentAgencyDebtSecuritiesMember 2021-06-30 0001693011 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-01-01 2020-12-31 0001693011 us-gaap:USTreasurySecuritiesMember 2020-01-01 2020-12-31 0001693011 inzy:USGovernmentAgencyDebtSecuritiesMember 2020-01-01 2020-12-31 0001693011 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-12-31 0001693011 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001693011 inzy:USGovernmentAgencyDebtSecuritiesMember 2020-12-31 0001693011 inzy:LongTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2020-01-01 2020-12-31 0001693011 inzy:LongTermInvestmentsMember inzy:USGovernmentAgencyDebtSecuritiesMember 2020-01-01 2020-12-31 0001693011 inzy:LongTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001693011 inzy:LongTermInvestmentsMember inzy:USGovernmentAgencyDebtSecuritiesMember 2020-12-31 0001693011 inzy:LongTermInvestmentsMember 2020-12-31 0001693011 us-gaap:EquipmentMember 2021-06-30 0001693011 us-gaap:EquipmentMember 2020-12-31 0001693011 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001693011 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001693011 inzy:ComputerEquipmentAndSoftwareMember 2021-06-30 0001693011 inzy:ComputerEquipmentAndSoftwareMember 2020-12-31 0001693011 us-gaap:LeaseholdImprovementsMember 2021-06-30 0001693011 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-06-30 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-06-30 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-06-30 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2021-06-30 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-06-30 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2021-06-30 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-06-30 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-06-30 0001693011 us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-12-31 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2020-12-31 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2020-12-31 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001693011 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001693011 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001693011 inzy:YaleUniversityMember 2021-01-01 2021-06-30 0001693011 inzy:YaleUniversityMember us-gaap:LicenseMember 2021-01-01 2021-06-30 0001693011 inzy:YaleUniversityMember 2021-06-30 0001693011 inzy:YaleUniversityMember us-gaap:CollaborativeArrangementMember 2019-02-28 0001693011 inzy:YaleUniversityMember us-gaap:CollaborativeArrangementMember 2019-02-01 2019-02-28 0001693011 inzy:YaleUniversityMember us-gaap:CollaborativeArrangementMember 2021-04-01 2021-06-30 0001693011 inzy:YaleUniversityMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-06-30 0001693011 inzy:YaleUniversityMember us-gaap:CollaborativeArrangementMember 2020-04-01 2020-06-30 0001693011 inzy:YaleUniversityMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-06-30 utr:sqft 0001693011 inzy:OfficeSpaceMember stpr:MA 2021-01-01 0001693011 inzy:OfficeSpaceMember stpr:MA 2021-01-01 2021-01-01 0001693011 inzy:OfficeSpaceMember stpr:MA 2021-01-01 2021-06-30 0001693011 inzy:LaboratorySpaceMember stpr:MA 2021-01-01 0001693011 inzy:LaboratorySpaceMember stpr:MA 2021-01-01 2021-01-01 0001693011 inzy:RestrictedCashMember us-gaap:LetterOfCreditMember 2021-06-30 0001693011 inzy:RestrictedCashMember us-gaap:LetterOfCreditMember 2020-12-31 xbrli:pure 0001693011 2021-01-01 2021-01-01 0001693011 2021-01-01 0001693011 srt:MaximumMember inzy:SeriesATwoConvertiblePreferredStockMember 2018-11-30 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember 2018-11-30 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember 2018-11-01 2018-11-30 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember 2019-03-31 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember 2019-03-01 2019-03-31 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember 2020-06-01 2020-06-30 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember srt:MinimumMember 2018-11-30 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember srt:MaximumMember 2020-07-31 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember inzy:AlexionPharmaceuticalsIncMember 2020-07-31 0001693011 us-gaap:IPOMember 2020-07-28 0001693011 2020-07-28 0001693011 inzy:TwoThousandTwentyStockIncentivePlanMember 2020-07-23 0001693011 inzy:TwoThousandSeventeenStockIncentivePlanMember 2020-07-23 0001693011 inzy:TwoThousandTwentyStockIncentivePlanMember 2020-07-23 2020-07-23 0001693011 inzy:TwoThousandTwentyStockIncentivePlanMember 2021-01-01 0001693011 inzy:TwoThousandSeventeenEquityIncentivePlanMember 2020-07-31 0001693011 inzy:TwoThousandSeventeenEquityIncentivePlanMember 2020-07-17 0001693011 inzy:TwoThousandTwentyStockIncentivePlanMember 2021-06-30 0001693011 srt:MinimumMember 2021-04-01 2021-06-30 0001693011 srt:MinimumMember 2020-04-01 2020-06-30 0001693011 srt:MinimumMember 2021-01-01 2021-06-30 0001693011 srt:MinimumMember 2020-01-01 2020-06-30 0001693011 srt:MaximumMember 2021-04-01 2021-06-30 0001693011 srt:MaximumMember 2021-01-01 2021-06-30 0001693011 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001693011 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001693011 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001693011 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001693011 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001693011 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001693011 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001693011 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001693011 inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember 2020-07-23 0001693011 inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember 2020-07-23 2020-07-23 0001693011 inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-01-01 0001693011 inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-01-01 2021-06-30 0001693011 inzy:SeriesAConvertiblePreferredStockMember 2020-04-01 2020-06-30 0001693011 inzy:SeriesAConvertiblePreferredStockMember 2020-01-01 2020-06-30 0001693011 inzy:SeriesATwoConvertiblePreferredStockMember 2020-01-01 2020-06-30 0001693011 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001693011 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001693011 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001693011 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001693011 srt:MaximumMember 2021-01-01 2021-01-01

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________________ to _____________________

Commission File Number: 001-39397

 

INOZYME PHARMA, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

38-4024528

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

321 Summer Street, Suite 400

Boston, Massachusetts

02210

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (857330-4340

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

INZY

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  ☒    No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  ☒    No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

  

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes      No  

As of August 6, 2021, the registrant had 23,661,600 shares of common stock, $0.0001 par value per share, outstanding.

 

 

 


 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance. All statements, other than statements of historical fact, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “outlook,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and the negative version of these words and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. We believe these factors include but are not limited to those described in the “Risk Factors” section in our most recent Annual Report on Form 10-K and include, among other things:

 

the timing and conduct of our planned Phase 1/2 clinical trials of INZ-701 for ENPP1 and ABCC6 Deficiencies, including statements regarding the timing of initiation, enrollment and completion of the clinical trials and the period during which the results of the clinical trials will become available;

 

the timing of our additional planned clinical trial applications for INZ-701 for ENPP1 Deficiency;

 

the timing and conduct of our planned later stage clinical trials of INZ-701 for patients with ENPP1 and ABCC6 Deficiencies;

 

our plans to conduct research and preclinical testing of INZ-701 for additional indications;

 

our plans to conduct research and preclinical testing of other product candidates;

 

the timing of, and our ability to obtain and maintain, marketing approvals of INZ-701, and the ability of INZ-701 and our other product candidates to meet existing or future regulatory standards;

 

our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents and short-term investments;

 

the potential advantages of our product candidates;

 

the rate and degree of market acceptance and clinical utility of our product candidates;

 

our estimates regarding the potential market opportunity for our product candidates;

 

our commercialization and manufacturing capabilities and strategy;

 

our intellectual property position;

 

the impact of COVID-19 on our business and operations;

 

our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;

 

our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

 

the impact of government laws and regulations;

 

our competitive position; and

 

our expectations regarding the time during which we will be an emerging growth company under the Jumpstart our Business Startups Act of 2012.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in our most recent Annual Report on Form 10-K, particularly in the “Risk Factors” section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments we may make or enter into.

You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report on Form 10-Q, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

i


Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

1

Item 1.

Financial Statements (Unaudited)

1

 

Condensed Consolidated Balance Sheets

1

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

2

 

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

3

 

Condensed Consolidated Statements of Cash Flows

4

 

Notes to Unaudited Condensed Consolidated Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

16

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

26

Item 4.

Controls and Procedures

26

PART II.

OTHER INFORMATION

27

Item 1A.

Risk Factors

27

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

27

Item 6.

Exhibits

28

Signatures

29

 

 

 

ii


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

INOZYME PHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except share and per share data)

(Unaudited)

 

 

 

June 30,

2021

 

 

December 31,

2020

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

26,239

 

 

$

28,040

 

Short-term investments

 

 

111,225

 

 

 

119,657

 

Prepaid expenses and other current assets

 

 

3,498

 

 

 

3,282

 

Total current assets

 

 

140,962

 

 

 

150,979

 

Property and equipment, net

 

 

2,611

 

 

 

2,648

 

Right-of-use assets

 

 

2,248

 

 

 

 

Restricted cash

 

 

354

 

 

 

354

 

Long-term investments

 

 

 

 

 

12,199

 

Prepaid expenses, net of current portion

 

 

2,084

 

 

 

3,183

 

Total assets

 

$

148,259

 

 

$

169,363

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

796

 

 

$

3,069

 

Accrued expenses

 

 

5,485

 

 

 

6,904

 

Operating lease liabilities

 

 

691

 

 

 

 

Total current liabilities

 

 

6,972

 

 

 

9,973

 

Operating lease liabilities, net of current portion

 

 

3,013

 

 

 

1,287

 

Total liabilities

 

 

9,985

 

 

 

11,260

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred Stock, $0.0001 par value – 5,000,000 shares authorized at June 30, 2021 and December 31, 2020; No shares issued and outstanding at June 30, 2021 or December 31, 2020

 

 

 

 

 

 

Common Stock, $0.0001 par value – 200,000,000 shares authorized at June 30, 2021 and December 31, 2020; 23,570,593 shares issued and outstanding at June 30, 2021 and 23,384,969 shares issued and outstanding at December 31, 2020

 

 

2

 

 

 

2

 

Additional paid in-capital

 

 

252,920

 

 

 

249,175

 

Accumulated other comprehensive income

 

 

18

 

 

 

2

 

Accumulated deficit

 

 

(114,666

)

 

 

(91,076

)

Total stockholders’ equity

 

 

138,274

 

 

 

158,103

 

Total liabilities and stockholders’ equity

 

$

148,259

 

 

$

169,363

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

1


INOZYME PHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(amounts in thousands, except share and per share data)

(Unaudited)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

8,220

 

 

$

7,877

 

 

$

14,823

 

 

$

14,283

 

General and administrative

 

 

4,435

 

 

 

1,671

 

 

 

8,804

 

 

 

3,171

 

Total operating expenses

 

 

12,655

 

 

 

9,548

 

 

 

23,627

 

 

 

17,454

 

Loss from operations

 

 

(12,655

)

 

 

(9,548

)

 

 

(23,627

)

 

 

(17,454

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

58

 

 

 

71

 

 

 

121

 

 

 

242

 

Other income (expenses)

 

 

57

 

 

 

4

 

 

 

(84

)

 

 

1

 

Other income (expense), net

 

 

115

 

 

 

75

 

 

 

37

 

 

 

243

 

Net loss

 

$

(12,540

)

 

$

(9,473

)

 

$

(23,590

)

 

$

(17,211

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gains (losses) on available-for-sale securities

 

 

6

 

 

 

(15

)

 

 

16

 

 

 

8

 

Total other comprehensive income (loss)

 

 

6

 

 

 

(15

)

 

 

16

 

 

 

8

 

Comprehensive loss

 

$

(12,534

)

 

$

(9,488

)

 

$

(23,574

)

 

$

(17,203

)

Net loss attributable to common stockholders—basic

   and diluted

 

$

(12,540

)

 

$

(9,473

)

 

$

(23,590

)

 

$

(17,211

)

Net loss per share attributable to common

   stockholders—basic and diluted

 

$

(0.53

)

 

$

(7.57

)

 

$

(1.01

)

 

$

(14.01

)

Weighted-average common shares outstanding—basic

   and diluted

 

 

23,490,591

 

 

 

1,251,244

 

 

 

23,460,218

 

 

 

1,228,296

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

2


 

INOZYME PHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(amounts in thousands, except share data)

(Unaudited)

 

 

Series A Convertible Preferred Stock

 

 

Series A-2 Convertible Preferred Stock

 

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders’

Equity

 

 

Shares

 

Amount

 

 

Shares

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

(Deficit)

 

Balance at December 31, 2020

 

 

$

 

 

 

 

$

 

 

 

 

23,384,969

 

 

$

2

 

 

$

249,175

 

 

$

2

 

 

$

(91,076

)

 

$

158,103

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,577

 

 

 

 

 

 

 

 

 

1,577

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

 

 

 

88,734

 

 

 

 

 

 

249

 

 

 

 

 

 

 

 

 

249

 

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10

 

 

 

 

 

 

10

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(11,050

)

 

 

(11,050

)

Balance at March 31, 2021

 

 

$

 

 

 

 

$

 

 

 

 

23,473,703

 

 

$

2

 

 

$

251,001

 

 

$

12

 

 

$

(102,126

)

 

$

148,889

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,813

 

 

 

 

 

 

 

 

 

1,813

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

 

 

 

96,890

 

 

 

 

 

 

106

 

 

 

 

 

 

 

 

 

106

 

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

6

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(12,540

)

 

 

(12,540

)

Balance at June 30, 2021

 

 

$

 

 

 

 

$

 

 

 

 

23,570,593

 

 

$

2

 

 

$

252,920

 

 

$

18

 

 

$

(114,666

)

 

$

138,274

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2019

 

48,850,000

 

$

44,657

 

 

 

23,566,431

 

$

33,270

 

 

 

 

1,204,630

 

 

$

 

 

$

1,428

 

 

$

5

 

 

$

(34,652

)

 

$

(33,219

)

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

129

 

 

 

 

 

 

 

 

 

129

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

 

 

 

2,677

 

 

 

 

 

 

5

 

 

 

 

 

 

 

 

 

5

 

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

23

 

 

 

 

 

 

23

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(7,738

)

 

 

(7,738

)

Balance at March 31, 2020

 

48,850,000

 

$

44,657

 

 

 

23,566,431

 

$

33,270

 

 

 

 

1,207,307

 

 

$

 

 

$

1,562

 

 

$

28

 

 

$

(42,390

)

 

$

(40,800

)

Issuance of Series A-2 Convertible

   Preferred Stock, net of issuance costs

   of $0.1 million

 

 

 

 

 

 

 

 

23,566,431

 

 

33,638

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

120

 

 

 

 

 

 

 

 

 

120

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

 

 

 

137,397

 

 

 

 

 

 

149

 

 

 

 

 

 

 

 

 

149

 

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(15

)

 

 

 

 

 

(15

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,473

)

 

 

(9,473

)

Balance at June 30, 2020

 

48,850,000

 

$

44,657

 

 

 

47,132,862

 

$

66,908

 

 

 

 

1,344,704

 

 

$

 

 

$

1,831

 

 

$

13

 

 

$

(51,863

)

 

$

(50,019

)

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3


 

INOZYME PHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(amounts in thousands)

(Unaudited)

 

 

 

Six Months Ended

June 30,

 

 

 

2021

 

 

2020

 

Operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(23,590

)

 

$

(17,211

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

325

 

 

 

51

 

Stock-based compensation expense

 

 

3,390

 

 

 

249

 

Amortization of premiums and discounts on marketable securities

 

 

116

 

 

 

(81

)

Reduction in the carrying value of right-of-use assets

 

 

183

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

(216

)

 

 

(465

)

Accounts payable

 

 

(2,281

)

 

 

454

 

Accrued expenses

 

 

(1,142

)

 

 

2,105

 

Operating lease liabilities

 

 

(293

)

 

 

 

Prepaid expenses - noncurrent

 

 

1,099

 

 

 

 

Net cash used in operating activities

 

 

(22,409

)

 

 

(14,898

)

Investing activities